A simple urine test could diagnose celiac disease in children without blood draws. New findings published in Scientific Reports show that two specific molecules in urine—combined with a protein marker already measured in routine urine tests—can identify pediatric celiac disease with high accuracy.
For parents who have watched their children endure repeated blood draws during the diagnostic process, this represents a real shift. The research team from Bambino Gesù Children’s Hospital in Rome identified two microRNAs (miR-221-3p and miR-324-5p) in urine that, when measured alongside albuminuria, can detect celiac disease non-invasively.
What This Means for You
If you’re navigating diagnosis for your child right now, you know the drill: multiple clinic visits, blood draws that can be traumatic for young kids, waiting for results, possibly more blood work. This research points toward a future where diagnosis could start with a urine sample collected at home or in a doctor’s office without needles.
The test isn’t commercially available yet—this is early-stage research. But the accuracy is promising enough that it could change how pediatric gastroenterologists approach celiac screening, particularly for children who need repeated monitoring or those in whom blood draws are especially difficult.
The researchers found that measuring these two microRNAs together with albumin levels (a protein that shouldn’t normally appear in urine) creates a diagnostic model sensitive enough to distinguish children with celiac disease from healthy controls. This matters because current diagnosis requires blood tests for antibodies followed by an endoscopy with biopsy to confirm intestinal damage—a process that can take weeks or months and requires sedation for the endoscopy.
A urine-based screening test could make the path to diagnosis faster and less invasive. It could also make screening more accessible for children in settings where blood draws are logistically difficult or for families where medical anxiety is a barrier to testing.
Key Takeaways
- Two microRNAs in urine (miR-221-3p and miR-324-5p) combined with albumin can identify pediatric celiac disease
- The test requires only a urine sample—no blood draw needed
- This is research-stage technology, not yet available clinically
- The approach could make screening easier for children and enable better monitoring after diagnosis
- Blood tests and biopsy remain the current diagnostic standard
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What Are MicroRNAs and Why Do They Matter?
MicroRNAs (abbreviated miRNAs) are tiny molecules made of RNA—the same genetic material your cells use to read DNA instructions. Unlike the RNA that codes for proteins, microRNAs regulate which genes get turned on or off in your cells.
When tissues are damaged or diseased, cells release specific microRNAs into body fluids. In celiac disease, the intestinal damage triggered by gluten causes cells to release particular microRNAs that end up in urine. Think of them as molecular signatures of what’s happening inside the body.
The two microRNAs identified in this study—miR-221-3p and miR-324-5p—appear at different levels in the urine of children with celiac disease compared to healthy children. The researchers discovered these specific molecules by analyzing urine samples from pediatric celiac patients and controls, looking for patterns that could distinguish the two groups.
The Role of Albuminuria
Albuminuria means albumin (a protein normally kept in your bloodstream by healthy kidneys) is leaking into urine. In celiac disease, this can happen because the systemic inflammation affects kidney function.
The study notes that celiac disease can cause renal involvement—kidney-related complications—in children. Earlier research has found kidney problems in some celiac patients, including protein in the urine. By combining the microRNA measurements with albumin levels, the researchers created a more accurate diagnostic model than using any single marker alone.
This makes sense physiologically: celiac disease isn’t just an intestinal condition. It’s a systemic autoimmune response that can affect multiple organs. The kidneys filter blood constantly and reflect what’s happening throughout the body. Combining a marker of kidney involvement (albumin) with markers of cellular damage (microRNAs) gives a fuller picture of disease presence.
How the Diagnostic Model Works
The research team developed a diagnostic model—essentially a mathematical formula that weighs the levels of miR-221-3p, miR-324-5p, and albumin to produce a score indicating likelihood of celiac disease.
This type of model uses machine learning or statistical methods to find the optimal combination of markers. The algorithm learns from samples with known diagnoses (confirmed celiac disease versus healthy controls) and identifies patterns that best separate the two groups.
The researchers validated their model on separate groups of children to confirm it could accurately predict celiac status in samples it hadn’t been trained on. This validation step is crucial—it shows the test isn’t just memorizing the training data but genuinely detecting a biological signal of celiac disease.
Why Urine Instead of Blood?
Blood tests remain highly accurate for celiac disease, particularly the tissue transglutaminase antibody (tTG-IgA) test. But urine offers advantages beyond just avoiding needles.
MicroRNAs in urine are remarkably stable. They survive at room temperature and resist degradation, making them practical for clinical testing. Urine collection is non-invasive, can be done at home, and doesn’t require trained phlebotomists. For population screening or repeated monitoring, these logistics matter.
The study builds on growing evidence that celiac disease leaves detectable marks in urine beyond just kidney-related changes. Earlier research has explored various urinary biomarkers in celiac disease, and this work adds to that foundation by identifying specific microRNA signatures.
Clinical Pathway to Implementation
Before this becomes a routine test, researchers need to validate the findings in larger, more diverse populations of children. The study included patients from a single pediatric hospital in Rome, so replication in other populations—different ethnicities, ages, and geographic locations—is essential.
The test would also need to demonstrate performance characteristics that meet clinical standards: sensitivity (ability to correctly identify celiac patients) and specificity (ability to correctly rule out celiac in healthy children). The researchers report promising accuracy, but real-world validation in clinical settings will determine whether the test can replace or complement current diagnostic methods.
Regulatory approval would follow, requiring demonstration that the test is both accurate and reproducible across different laboratories. Only then could it become part of standard diagnostic protocols.
Connection to Body Composition Research
This isn’t the first time researchers have looked beyond traditional antibody tests to understand celiac disease in children. Earlier this year we covered research using bioelectrical impedance analysis to identify how celiac disease affects body composition in girls—another non-invasive approach to understanding disease impact beyond just intestinal damage.
Both studies reflect a broader shift toward understanding celiac disease as a systemic condition with measurable effects throughout the body, not just in the small intestine. These non-invasive assessment tools could eventually help clinicians monitor disease activity and treatment response without repeated blood draws or biopsies.
The Reality Check
As the parent of a child with celiac disease, I want to be clear about where this research stands. This is not a test you can request tomorrow. It’s a proof-of-concept study showing that a urine-based diagnostic approach is biologically feasible and potentially accurate.
The path from research findings to clinical implementation takes years. The test needs validation in larger studies, development into a standardized clinical assay, regulatory approval, and eventual adoption by healthcare systems. That timeline typically spans 5-10 years or more.
But the direction matters. Every research step toward easier, more accessible diagnosis benefits celiac families. Anything that reduces the burden of repeated blood draws on children, speeds time to diagnosis, or makes screening more practical in primary care settings moves us forward.
For now, if you suspect celiac disease in your child, the current diagnostic pathway remains the standard: serological testing (blood work for celiac antibodies), followed by endoscopic biopsy if antibodies are positive. Continue to work with your child’s gastroenterologist and follow established protocols.
What to Watch For
As this research advances, look for follow-up studies validating the microRNA test in larger, more diverse pediatric populations. Pay attention to whether research teams outside Italy can replicate these findings—independent validation is crucial for any new diagnostic method.
Also watch for research exploring whether urinary microRNAs could monitor disease activity in children already diagnosed with celiac disease. If these markers reflect intestinal inflammation, they might help doctors assess how well the gluten-free diet is working without requiring follow-up biopsies or repeated blood tests.
The ultimate goal isn’t just easier diagnosis—it’s better ongoing care. Tools that make monitoring simpler and less invasive could help families and doctors stay on top of disease management more effectively.
Related Coverage
References
Paolini A, Bruno SP, Felli C, Sandal S, Rostami-Nejad M, Muzi C, Cheri E, Ferretti F, Masotti A, Baldassarre A. Urinary miR-221-3p and miR-324-5p in combination with albuminuria as a promising model for non-invasive diagnosis of pediatric celiac disease. Scientific Reports. 2026 May 19. doi: 10.1038/s41598-026-53245-5. Available at: https://pubmed.ncbi.nlm.nih.gov/42156871/